“We were given a gift to be able to solve a big problem, and though the road to getting a device to market is often a bumpy one, we have never lost our resolve to keep moving forward.”
That focus from Madorra, a Fogarty Institute graduate aiming to improve the quality of life for breast cancer survivors and post-menopausal women,
It’s often said that the only constant is change. Here at the Fogarty Institute, we embrace that sentiment because in the world of medtech, change is inevitable to continue to enhance patient care. That’s why we are delighted with recent advances in funding – while the funding environment can be challenging, the industry has demonstrated resilience and agility as startups seek to get innovative devices to market.
Fogarty Institute graduate Alydia Health, formerly known as InPress Technologies, is well on its way to conducting a pivotal study, thanks to the closing of a recent $10M Series B round led by Global Health Investment Fund. The U.S. study aims to prove the safety and efficacy of its novel device, the Jada System, in stopping postpartum hemorrhage (PPH) —
A former Stanford Biodesign Fellow and Fogarty Institute entrepreneur, 32-year-old Holly Rockweiler has already had remarkable accomplishments early in her career, fluently moving her startup to the next level.
Most notably, Holly has parlayed Madorra’s impressive study results into securing funding, including winning several pitching competitions, despite the chronically challenging medtech fundraising environment.
As the first and only device cleared by the FDA to collect cells from the fallopian tubes, the Mako 7 device, originally developed by nVision, a Fogarty Institute graduate, offers a potential platform for earlier detection of ovarian cancer. The company was recently acquired by Boston Scientific, as the device represents an exciting opportunity for the company to expand its focus on women’s health and provides a potential platform to improve care for women worldwide.